Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

8.450
-0.665-7.30%
Volume:1.34M
Turnover:11.39M
Market Cap:8.89B
PE:-19.50
High:9.160
Open:9.115
Low:8.310
Close:9.115
52wk High:19.860
52wk Low:7.675
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:0.92
T/O Rate:0.13%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.433
ROE:-28.59%
ROA:-19.64%
PB:3.34
PE(LYR):-19.50
PS:8015.14

Loading ...

ASCLETIS-B Issues 0.22 Million New Shares on Option Exercises in September, Maintains Compliant Public Float

Bulletin Express
·
Oct 06

Ascletis Pharma Climbs Nearly 11% in Afternoon Trading as Preclinical Data for Weight-Loss Combination Therapy ASC36_35FDC Is Released

Deep News
·
Oct 06

Hong Kong Stock Movers: Innovative Drug Stocks Extend Gains as BofA Points to Three Major Recent Partnerships Strengthening Sector Momentum and ESMO Set to Bring Dense Catalysts

Stock News
·
Oct 06

HK Movers | Innovative Drug Stocks Rally Broadly; GENSCRIPT BIO Jumps Over 6% to New High

Tiger Newspress
·
Oct 06

NIO-SW Delivers 300,301 Vehicles in First Three Quarters, Up 49.2% Year-on-Year

Stock News
·
Oct 05

Ascletis Pharma Presents Preclinical Data for Weight Loss Drug at European Conference

MT Newswires Live
·
Oct 02

Ascletis’ ASC36_35FDC Shows Up to 24.8% Weight-Loss and Once-Quarterly Potential in Preclinical Studies

Bulletin Express
·
Oct 02

Ascletis Pharma-B Reports Promising Preclinical Data for ASC36_35FDC at EASD 2026, Showing Potential for Monthly to Quarterly Dosing and Robust Weight Loss

Stock News
·
Oct 02

Ascletis Pharma Widens H1 2026 Loss to RMB 0.32 Billion as R&D Outlays Double; Cash Pile Rises to RMB 2.31 Billion

Bulletin Express
·
Sep 29

Ascletis Pharma Reports Positive Results From ASC50 Psoriasis Trial

MT Newswires Live
·
Sep 29

Ascletis Reports 48.9% Placebo-Adjusted PASI Reduction in U.S. Proof-of-Concept Study for First-in-Class Oral IL-17A Inhibitor ASC50

Bulletin Express
·
Sep 29

Ascletis Says ASC50 Cuts PASI Score 48.9% in 28-Day U.S. Plaque Psoriasis Study

Reuters
·
Sep 29

Ascletis Pharma-B (01672) Reports Positive 28-Day Proof-of-Concept Clinical Results for First-in-Class and Best-in-Class Oral Small Molecule IL-17A Inhibitor ASC50 in Treating Plaque Psoriasis in the United States

Stock News
·
Sep 29

Ascletis Announces Positive Results from 28-Day Proof-of-Concept Clinical Study in U.S. for Asc50, a First-in-Class and Best-in-Class Oral Small Molecule Il-17a Inhibitor for the Treatment of Plaque Psoriasis

THOMSON REUTERS
·
Sep 29

HK Stocks in Focus: Biopharma Sector Surges as 10 Ministries Unveil 15th Five-Year Plan; Analysts See Potential 'Claude Moment' for Industry

Stock News
·
Sep 18

Ascletis Pharma Surges on US Obesity Drug Trial Launch

Deep News
·
Sep 10

Ascletis Hits 4-Week High on Initiating US Phase I Study on Obesity Drug

Reuters
·
Sep 09

ASC36 Obesity Therapy Enters Phase I Trials in the US by Ascletis

Stock News
·
Sep 08

Ascletis Pharma - Initiates U.S. Phase I Study for Asc36 Oral Tablets for Obesity

THOMSON REUTERS
·
Sep 08

Ascletis Pharma Joins Two Chinese Stock Connect Programs

MT Newswires Live
·
Sep 07